Primary Diffuse Large B-Cell Lymphoma of the CNS · line 2 · Salvage HD-MTX-based re-induction for relapsed PCNSL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-R-MPV-SALVAGE-PCNSL |
| ID | IND-PCNSL-2L-RMPV-SALVAGE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-PCNSL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-CNS-2025 |
Notes
Standard-track 2L PCNSL for chemosensitive late-relapse (>12 mo post-1L). AutoSCT consolidation preferred for fit; ibrutinib/lenalidomide-R for older. WBRT only when no other option.
Used By
Algorithms
ALGO-PCNSL-2L- ALGO-PCNSL-2L